Showing recent highlights
What's New
PubMed · June 12, 2026
Researchers looked at a traditional Chinese herb called Rhizoma Drynariae — sometimes called drynaria — and found that extracts from it appeared to improve bone density and bone strength in rats with osteoporosis, which is a condition where bones become weak and brittle and break more easily. This is interesting because the herb seemed to affect several measures of bone health at once, which might eventually point scientists toward new ways to support bone health in people. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 2, 2026
Researchers found that an AI-powered chatbot designed to teach people with osteoporosis — a condition where bones become weak and fragile — how to manage their health performed comparably to traditional face-to-face education from nurses, while also freeing up significant nursing time. People who used the chatbot showed similar improvements in their knowledge about osteoporosis and were just as likely to stick to their care routines over the following months. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that a newer version of a bone-strengthening drug called Bmab 1000 worked about as well as the original drug (denosumab) at improving bone density — the measure of how strong and dense bones are — in women whose bones had become fragile after menopause, which is called osteoporosis. They also found that people who switched from the original drug to Bmab 1000 did not seem to have problems with safety, which could eventually matter because biosimilar drugs (essentially lower-cost copies of an original drug) might make treatment more accessible for people with osteoporosis. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that a biosimilar version of denosumab — a medication used to treat osteoporosis by slowing bone loss — worked just as well and was just as safe as the original brand-name version, based on data from nearly 1,800 patients. Both versions produced similar improvements in bone density (a measure of how strong and solid bones are) at the spine, hip, and femoral neck (the top of the thigh bone), and side effects were comparable between the two. This matters because biosimilars are often less expensive than the original medication, which could make treatment more accessible for people with osteoporosis. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 22, 2026
A review of studies found that older men with osteoporosis — a condition where bones become weak and fragile — are often not diagnosed or treated, even though their risk of breaking a bone is significant. Researchers found that certain bone medications, as well as resistance exercise (like weight training for 60–90 minutes a day), showed some promise in strengthening bones, though the evidence wasn't strong enough to confirm they reliably prevent fractures. Because research in this area is still limited, men with osteoporosis may want to ask their doctor what treatment and lifestyle options have been considered for them specifically.
Ask your doctor: Ask the doctor whether the patient should be screened for osteoporosis and what combination of medicines and lifestyle changes would work best to prevent fractures.
What's New
PubMed · May 20, 2026
A study looked at whether taking calcium, vitamin D, or both together could help prevent broken bones and falls in adults, pulling together results from 69 studies with over 153,000 people. Researchers found that for most adults who were generally healthy and not already at high risk of fractures, these supplements had little to no effect on preventing broken bones. People with osteoporosis — a condition that weakens bones and makes them more likely to break — may want to ask their doctor whether supplements are the right approach for their specific situation, since this research suggests they don't work the same way for everyone.
Ask your doctor: Ask the doctor whether the patient should be taking calcium and vitamin D together to help prevent broken bones, or if one alone would work just as well.
What's New
PubMed · May 4, 2026
Researchers carefully reviewed the tools doctors use to measure how much osteoporosis — a condition that weakens bones and raises the risk of fractures — affects a person's overall wellbeing and daily life. They found that none of the existing measurement tools performed strongly enough across all the important quality checks, which means it's currently hard to know if we're accurately capturing how people with osteoporosis truly feel. Someday, having a reliable, well-tested tool like this could help doctors better understand whether treatments are actually improving patients' lives, not just their bone strength. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · May 4, 2026
This study looked at three bone-strengthening medications — denosumab (brand name Prolia), zoledronic acid (Reclast), and alendronate (Fosamax) — in men with osteoporosis, a condition where bones become weak and more likely to break. All three medications improved bone density (a measure of how strong and solid bones are) after 12 months, with no dramatic differences between them, though zoledronic acid caused more side effects than the other two. This is a comparison update rather than a brand-new treatment option, giving doctors useful information to help choose the best fit for individual male patients.
Ask your doctor: Ask the doctor whether denosumab, alendronate, or zoledronic acid might work best for strengthening the patient's bones if the patient has been diagnosed with osteoporosis.
Medications
PubMed · May 4, 2026
This is about updated national guidelines from Morocco for treating osteoporosis — a condition where bones become weak and fragile — in women after menopause. The guidelines bring together expert recommendations on how to better identify who is at risk for bone fractures and when to use different types of bone-strengthening treatments. This is a guideline update, not a new medication, meaning doctors now have a clearer, more modern roadmap to help their patients.
What's New
PubMed · May 1, 2026
Researchers looked at whether romosozumab, a bone-strengthening medication approved for osteoporosis (a condition where bones become weak and brittle), might help protect the bone around screws used in spinal surgery — which is a real challenge for people with osteoporosis because their bones don't grip the screws as well. Using virtual computer simulations on scans from real patients, they found some promising signs that the medication could improve bone strength in those critical areas around the screws. This is exciting to think about because better bone around surgical hardware could someday mean safer spine surgeries for people with osteoporosis, but this is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 1, 2026
Researchers looked at 20 studies that tested whether artificial intelligence — computer programs that learn to spot patterns — could analyze bone scans and predict who is most likely to break a bone from osteoporosis, a condition that makes bones fragile and easy to fracture. The interesting finding was that when these AI tools combined information from imaging scans with a person's health details, they got noticeably better at identifying fracture risk than traditional bone density tests alone, which don't always catch people who are quietly at high risk. Someday this approach might help doctors spot vulnerable patients earlier, before a painful fracture happens — but this is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 1, 2026
Researchers looked at whether two types of bone scans — one using MRI and one using CT — could predict which people with osteoporosis (a condition that makes bones weak and brittle) were more likely to break another bone after a procedure to stabilize a spinal fracture. They found that both scan measurements were fairly good at spotting people at higher risk, which is interesting because it could someday help doctors identify who needs extra attention after that kind of treatment. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · May 1, 2026
This is about updated guidelines for treating osteoporosis — a condition where bones become weaker and more likely to break — especially in regular (primary care) doctor settings. Four medical societies worked together to create agreed-upon recommendations covering how to identify people at risk, when to start treatment, and how to keep track of patients over time. This is a guideline update, not a new medication, and it aims to close the gap between how osteoporosis is currently diagnosed and treated versus how it should be.
Ask your doctor: Ask the doctor whether the patient should get a bone density test to check whether osteoporosis might be something the patient needs to know about.
What's New
PubMed · May 1, 2026
Researchers found that postmenopausal women at high risk for broken bones who took the bone-strengthening drug romosozumab for just 3 months saw similar improvements in hip bone density (a measure of how strong and solid bones are) compared to women who took it for a full 12 months. This could matter for people with osteoporosis — a condition where bones become weak and fragile — because a shorter treatment course might make the medication easier to stick with and potentially less costly. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed (Open Access Guidelines) · May 1, 2026
Researchers found that a newer ultrasound-based bone scanning technology called REMS measures bone strength in a way that closely matches results from DXA, the standard bone density scan used to diagnose osteoporosis (a condition where bones become weak and more likely to break). This matters because REMS doesn't use radiation like DXA does, so if it proves reliable, it could one day offer a safer or more accessible way to check bone health — especially for people who need regular monitoring. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · April 30, 2026
Researchers found that people with higher blood levels of a protein called α-Klotho — which acts like a natural marker of how well the body is aging — were significantly less likely to experience frailty, a condition where the body becomes weaker and more vulnerable over time. For people with chronic kidney disease, who often have lower levels of this protein and face a higher risk of frailty and physical decline, this connection could someday point toward new ways of understanding or tracking their health. This is early research and hasn't yet changed treatment guidelines.
Lifestyle
PubMed · April 23, 2026
Researchers found that eating about 50 to 100 grams of prunes per day — that's roughly 5 to 10 prunes — may modestly help preserve bone density in postmenopausal women, particularly in the lower spine. The benefit was described as 'borderline significant,' meaning the results are promising but not yet strong enough to be considered definitive. The study pooled results from 11 smaller studies involving 747 participants to reach these findings.
What's New
PubMed · April 22, 2026
Researchers found that postmenopausal women with osteoporosis who took oral bisphosphonates — a type of bone-strengthening medication — for more than 5 years continued to improve their bone density, which could potentially lower their risk of certain fractures. However, the same extended use was also linked to a higher risk of atypical fractures, meaning unusual stress fractures in the thigh bone that don't happen the usual way. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether the patient should continue taking bisphosphonates beyond 5 years, or if there are risks like jaw bone problems or unusual fractures that become more likely with longer use.
Medications
PubMed · April 3, 2026
This research looks at a group of bone-building medications — including teriparatide (brand name Forteo), abaloparatide (Tymlos), and romosozumab (Evenity) — used as the *first* treatment for people with osteoporosis who are at very high risk of breaking a bone. The study, which combined results from six trials involving nearly 18,000 people, found that starting with one of these bone-building drugs (rather than the more traditional bone-protecting drugs) significantly reduced the chances of fractures in the spine, hip, and elsewhere. This is more of a strategy update — it supports the idea that for people at the highest risk, leading with these bone-building medications from the start may offer better protection than the usual approach.
Ask your doctor: Ask the doctor whether starting the patient on an anabolic bone-building medication like teriparatide or abaloparatide might be better than other osteoporosis drugs if the patient is at very high risk for fractures.
What's New
PubMed · April 1, 2026
Researchers studied people who didn't yet have COPD (a serious lung disease that makes breathing difficult) and found that early, subtle lung damage — the kind that doesn't cause symptoms yet — was linked to lower bone density, meaning weaker bones that are more likely to break. This is interesting because it hints that lung and bone health may be connected earlier than doctors previously thought, which could someday help identify people at risk for both problems at the same time. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · April 1, 2026
This is about romosozumab (brand name Evenity), an injection used to treat osteoporosis — a condition where bones become weak and brittle. Two studies found that when the injection is given in the upper arm, people tend to feel noticeably more pain and have more skin reactions at the injection spot compared to getting it in the abdomen (belly area), though the medication works just as well either way. This is a safety update about injection comfort, not a change in how well the treatment works.
Ask your doctor: Ask the doctor whether the patient should get the patient's romosozumab injections in the patient's abdomen instead of the patient's upper arm to help reduce injection pain.
What's New
PubMed · April 1, 2026
Researchers found that two bone-strengthening medications used for osteoporosis in women after menopause — romosozumab and teriparatide — appear to work about equally well at reducing fractures in the spine, hip, and other bones, and neither seemed significantly safer or riskier than the other when it came to serious side effects or serious heart problems like heart attacks or strokes. This could matter for people with osteoporosis because it suggests these two treatments may be comparable options, giving doctors and patients more flexibility when choosing a plan that fits individual needs. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · April 1, 2026
A study found that smoking significantly raises the risk of broken bones — especially hip fractures — in both men and women, with the effect being even stronger in men. Researchers also found that people who had quit smoking had a noticeably lower fracture risk than those who still smoked, suggesting that quitting may help protect bones over time. People with osteoporosis (a condition where bones become weak and fragile) may want to ask their doctor how their smoking history factors into their overall bone health assessment.
What's New
PubMed (Open Access Guidelines) · April 1, 2026
Researchers found that resistance training — exercises like lifting weights or using resistance bands — may help older adults who have both weak muscles and fragile bones at the same time, a combination sometimes called osteosarcopenia. All four studies reviewed showed that this type of exercise had a positive effect on both muscle and bone health in people aged 65 and older, which matters because having both conditions together raises the risk of falls, fractures, and serious decline in health. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · March 31, 2026
Researchers found that when postmenopausal women with osteopenia — a condition where bones are weaker than normal but not yet at the level of osteoporosis — inhaled steam from sulfur-rich mineral water for 12 days in a row, their blood showed significant drops in markers of inflammation and oxidative stress (cell damage caused by harmful molecules), along with changes in markers related to bone health. The treatment appeared to be well tolerated with no early side effects reported. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · March 25, 2026
Researchers looked at all the available studies on screening women for osteoporosis — a condition where bones become weaker and more likely to break — to figure out which approaches to finding it early actually work and are worth the cost. They found that the evidence base is still being built, and there are open questions about how well different screening methods reach all groups of women fairly. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · March 20, 2026
Researchers looked at data from nearly 100,000 people across 39 studies and found an interesting pattern: people with a lower body weight (BMI is a number calculated from height and weight) had about three times the risk of developing osteoporosis — a condition where bones become weak and fragile — while people who were overweight had about half the risk. Surprisingly, underweight men appeared even more vulnerable than underweight women, which challenges the common assumption that osteoporosis is mainly a women's concern. Scientists think this might someday help doctors better identify who is most at risk for bone loss, though exactly why body weight seems to affect bone strength in this way still needs more investigation. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · March 16, 2026
Researchers are planning a large, careful study to find out whether digital tools — things like apps, online programs, or wearable devices — might help people with rheumatoid arthritis (a condition where the immune system attacks the joints, causing pain and stiffness) feel better and move more easily. If these tools turn out to be helpful, they could someday make support more accessible for people who struggle to get to clinics regularly. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · March 7, 2026
Researchers looking at 21 studies and over 23,000 people found that those with low bone density — meaning weaker, thinner bones, the kind seen in osteoporosis — were about twice as likely to also have calcium buildup in their heart arteries, which is an early warning sign of heart disease. The connection was even stronger when bone density was measured at the hip, suggesting that bone health and heart artery health may share some underlying causes, which could someday help doctors identify people at risk for both conditions at the same time. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · March 5, 2026
A study found that biosimilar versions of Prolia — lower-cost medications made to work just like the original brand-name drug — are just as effective and safe as Prolia itself for treating osteoporosis in postmenopausal women. Osteoporosis is a condition where bones become weak and brittle, and these medications work by helping to slow bone loss and increase bone density (how strong and solid bones are). Researchers say these biosimilars could be a more affordable option for people managing this condition, though more long-term research is still needed.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.